Published in Gastric Cancer on July 04, 2014
The influence of marital status on the stage at diagnosis, treatment, and survival of adult patients with gastric cancer: a population-based study. Oncotarget (2017) 0.83
Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer. BMC Cancer (2016) 0.81
Correlation of genetic polymorphism of vascular endothelial growth factor gene with susceptibility to lung cancer. Cancer Gene Ther (2015) 0.80
Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol (2015) 0.78
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract (2016) 0.77
The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1 (No correlation coefficient between VEGF and PROK1). Oncotarget (2015) 0.77
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. World J Gastroenterol (2016) 0.76
Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis. Mediators Inflamm (2016) 0.76
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Invest New Drugs (2015) 0.75
Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients. Biomed Res Int (2016) 0.75
Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. J Exp Clin Cancer Res (2016) 0.75
Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement. Nutrients (2017) 0.75
Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. Oncotarget (2017) 0.75
Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol (2015) 0.75
Ramucirumab (Cyramza): A Breakthrough Treatment for Gastric Cancer. P T (2015) 0.75
α-Actinin-4 promotes metastasis in gastric cancer. Lab Invest (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res (2005) 4.38
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol (2012) 2.45
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
The role of neuropilins in cancer. Mol Cancer Ther (2006) 2.28
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am (2013) 1.74
Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol (2004) 1.61
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer (2002) 1.47
Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control (2007) 1.45
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res (2007) 1.41
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer (2014) 1.41
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res (2012) 1.32
Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer (1998) 1.30
Characteristics of gastric cancer in Asia. World J Gastroenterol (2014) 1.26
Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25
Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg (2002) 1.24
Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett (2000) 1.03
Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer (2006) 1.02
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol (2010) 1.01
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol (2012) 1.01
Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol (1999) 0.98
Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer (2011) 0.92
A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther (2013) 0.90
Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol (2010) 0.89
Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res (2008) 0.87
The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett (2003) 0.87
Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer (1999) 0.84
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cancer Lett (2012) 0.84
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep (2012) 0.84
Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. Exp Mol Med (2013) 0.84
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg (2009) 0.83
Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed hep G2 cells. Am J Physiol (1999) 0.83
Lentivirus-mediated siRNA targeting VEGF inhibits gastric cancer growth in vivo. Oncol Rep (2012) 0.83
Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol (2012) 0.81
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist (2013) 0.78
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg (2012) 2.85
Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol (2007) 2.25
New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol (2010) 1.80
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery (2010) 1.67
Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer (2006) 1.66
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res (2008) 1.65
Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res (2005) 1.51
Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol (2012) 1.51
Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov (2013) 1.44
Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys (2007) 1.42
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One (2009) 1.40
An evidence-based review of the surgical treatment of gastric adenocarcinoma. J Gastrointest Surg (2011) 1.39
Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol (2008) 1.28
Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys (2008) 1.27
Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol (2014) 1.17
D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol (2012) 1.11
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res (2010) 1.01
Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther (2013) 0.98
Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res (2010) 0.97
Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med (2007) 0.95
β-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist (2013) 0.94
Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg (2002) 0.93
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer (2002) 0.93
Noncurative gastrectomy for gastric adenocarcinoma should only be performed in highly selected patients. Ann Surg Oncol (2013) 0.93
An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys (2009) 0.93
Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. Int J Radiat Oncol Biol Phys (2009) 0.91
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol (2013) 0.90
Extended lymphadenectomy in gastric cancer is debatable. World J Surg (2013) 0.90
Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. Am J Surg Pathol (2012) 0.90
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer (2012) 0.89
Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction. Angiogenesis (2012) 0.88
Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer (2012) 0.87
Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 0.87
Esophageal reinforcement with an extracellular scaffold during total gastrectomy for gastric cancer. Ann Surg Oncol (2014) 0.86
Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol (2009) 0.86
Electrospun polystyrene nanofiber membrane with superhydrophobicity and superoleophilicity for selective separation of water and low viscous oil. ACS Appl Mater Interfaces (2013) 0.85
Leiomyoma and leiomyosarcoma arising from the round ligament of the uterus. J Am Coll Surg (2008) 0.84
CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. AJR Am J Roentgenol (2015) 0.83
D2 lymphadenectomy with surgical ex vivo dissection into node stations for gastric adenocarcinoma can be performed safely in Western patients and ensures optimal staging. Ann Surg Oncol (2013) 0.83
Surgical management of retroperitoneal and pelvic sarcomas. J Surg Oncol (2014) 0.82
Coalescence of two drops on partially wettable substrates. Langmuir (2012) 0.82
Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis. J Surg Res (2007) 0.81
Gravity-driven hybrid membrane for oleophobic-superhydrophilic oil-water separation and water purification by graphene. Langmuir (2014) 0.80
Current treatment for the local control of retroperitoneal sarcomas. J Am Coll Surg (2011) 0.79
Low-dose neoadjuvant external beam radiation therapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys (2010) 0.79
Comparison of Perioperative Radiation Therapy and Surgery Versus Surgery Alone in 204 Patients With Primary Retroperitoneal Sarcoma: A Retrospective 2-Institution Study. Ann Surg (2015) 0.78
Regional control of tumor growth. Mol Cancer Res (2010) 0.78
How closely should we follow gastric cancer patients following surgical resection? Ann Surg Oncol (2011) 0.77
Nanotextured pillars of electrosprayed bismuth vanadate for efficient photoelectrochemical water splitting. Langmuir (2015) 0.77
Novel composite layer based on electrospun polymer nanofibers for efficient light scattering. ACS Appl Mater Interfaces (2014) 0.77
Antibacterial and water purification activities of self-assembled honeycomb structure of aerosol deposited titania film. Environ Sci Technol (2012) 0.76
Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma. J Comput Assist Tomogr (2015) 0.75
Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors? Ann Surg Oncol (2007) 0.75
Staging gastric cancer patients after complete surgical resection: which system should we use? Ann Surg Oncol (2012) 0.75
The use of radiation therapy in the management of selected patients with atypical lipomas. Sarcoma (2013) 0.75
Release of Self-healing Agents in a Material: What Happens Next? ACS Appl Mater Interfaces (2017) 0.75
Modified En Bloc Spondylectomy for Tumors of the Thoracic and Lumbar Spine: Surgical Technique and Outcomes. J Bone Joint Surg Am (2017) 0.75
Supersonically blown ultrathin thorny devil nanofibers for efficient air cooling. ACS Appl Mater Interfaces (2014) 0.75
Fire-through Ag contact formation for crystalline Si solar cells using single-step inkjet printing. J Nanosci Nanotechnol (2012) 0.75
Laparoscopic Versus Open Surgery for Gastric Adenocarcinoma: Innovation Continues to Challenge Tradition. Ann Surg (2016) 0.75
Supersonically blown nylon-6 nanofibers entangled with graphene flakes for water purification. Nanoscale (2015) 0.75
Thermally induced superhydrophilicity in TiO2 films prepared by supersonic aerosol deposition. ACS Appl Mater Interfaces (2013) 0.75
IGF-I abuse in sport. Curr Drug Abuse Rev (2009) 0.75
Electrocatalytic reduction of CO2 by thiophene-substituted rhenium(i) complexes and by their polymerized films. Dalton Trans (2016) 0.75
Highly efficient wettability control via three-dimensional (3D) suspension of titania nanoparticles in polystyrene nanofibers. ACS Appl Mater Interfaces (2013) 0.75
Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg (2016) 0.75
Hybrid self-healing matrix using core-shell nanofibers and capsuleless microdroplets. ACS Appl Mater Interfaces (2014) 0.75
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg (2016) 0.75
Electrically-charged recyclable graphene flakes entangled with electrospun nanofibers for the adsorption of organics for water purification. Nanoscale (2015) 0.75
Dynamic electrowetting-on-dielectric (DEWOD) on unstretched and stretched teflon. Langmuir (2013) 0.75
Carbon- and oxygen-free Cu(InGa)(SSe)₂ solar cell with a 4.63% conversion efficiency by electrostatic spray deposition. ACS Appl Mater Interfaces (2014) 0.75